1-deoxynojirimycin has been researched along with globotriaosyl lysosphingolipid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benjamin, ER; Boudes, P; Brignol, N; Chang, HH; Fuller, M; Germain, DP; Giugliani, R; Hughes, DA; Khanna, R; Lockhart, DJ; Mehta, A; Nicholls, K; Sitaraman, SA; Soska, R; Valenzano, KJ; Young-Gqamana, B | 1 |
| Giese, AK; Grittner, U; Kolodny, E; Lackner, KJ; Lukas, J; Markoff, A; Mascher, H; Meyer, W; Rolfs, A; Saviouk, V; Wree, P | 1 |
| McCafferty, EH; Scott, LJ | 1 |
| Mignani, R | 1 |
1 review(s) available for 1-deoxynojirimycin and globotriaosyl lysosphingolipid
| Article | Year |
|---|---|
Migalastat: A Review in Fabry Disease.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Approval; Enzyme Replacement Therapy; Fabry Disease; Female; Glycolipids; Humans; Male; Middle Aged; Mutation; Sphingolipids; Trihexosylceramides | 2019 |
3 other study(ies) available for 1-deoxynojirimycin and globotriaosyl lysosphingolipid
| Article | Year |
|---|---|
Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Topics: 1-Deoxynojirimycin; Administration, Oral; alpha-Galactosidase; Animals; Fabry Disease; Glycolipids; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Reproducibility of Results; Sphingolipids; Sphingosine; Trihexosylceramides | 2013 |
Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Amino Acid Substitution; Fabry Disease; Glycolipids; Humans; Mutation; Phenotype; Protein Transport; Sphingolipids | 2013 |
[The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Disease Progression; Enzyme Replacement Therapy; Fabry Disease; Female; Glomerulosclerosis, Focal Segmental; Glycolipids; Heterozygote; Humans; Isoenzymes; Kidney Diseases; Male; Oxidative Stress; Podocytes; Recombinant Proteins; Sex Factors; Sphingolipids; Trihexosylceramides | 2019 |